Prevalence and association of frailty with clinical outcomes in myeloproliferative neoplasms: A population-based study

Researchers analyzing data from the Ontario cancer registry found that ET, PV, and MF patients have a substantially higher prevalence of frailty compared with matched controls (standardized mean difference 0.27, 0.27, and 0.28). Using Cox-proportional regression, frailty was also independently associated with worse overall survival after adjusting for age, sex, and comorbidities compared to fit patients (prefrail vs frail patients: HR 1.6 [95% CI: 1.3-1.9] vs 3.6 [2.9-4.4] in ET; 1.3 [1.1-1.5] vs 2.7 [2.1-3.4] in PV; and 1.2 [1.0-1.5] vs 2.0 [1.5-2.7] in MF).